{
    "title": "Prognostic Scores in Oncology: Key Prognostic Score Types",
    "category": "Clinical Oncology",
    "section": "Patient Assessment",
    "summary": "Comprehensive guide to major prognostic scoring systems in oncology, including disease-specific, organ-specific, and biomarker-integrated models.",
    "author": "OncoVISTA Team",
    "lastUpdated": "2023-11-15T00:00:00Z",
    "version": "2.0.0",
    "metadata": {
      "reviewStatus": "peer-reviewed",
      "readingTimeMinutes": 15,
      "relatedTopics": [
        "Performance Status Assessment",
        "Predictive Biomarkers in Oncology",
        "Geriatric Oncology Assessment"
      ]
    },
    "content": [
      {
        "type": "heading",
        "level": 1,
        "text": "Prognostic Scores in Oncology"
      },
      {
        "type": "heading",
        "level": 2,
        "text": "Topic 2: Key Prognostic Score Types"
      },
      {
        "type": "heading",
        "level": 2,
        "text": "1. Overview"
      },
      {
        "type": "paragraph",
        "text": "Prognostic tools in oncology vary widely based on cancer type, disease stage, and available diagnostics. They serve to stratify patient risk, guide treatment intensity, and support shared decision-making."
      },
      {
        "type": "paragraph",
        "text": "Modern scores range from simple clinical indices to genomically integrated models. They help predict outcomes such as:"
      },
      {
        "type": "list",
        "items": [
          "Overall survival (OS)",
          "Progression-free survival (PFS)",
          "Treatment toxicity risk",
          "Relapse likelihood"
        ]
      },
      {
        "type": "clinical_pearl",
        "text": "Prognostic scores should be interpreted in clinical context - they inform but don't dictate treatment decisions."
      },
      {
        "type": "heading",
        "level": 2,
        "text": "2. Disease-Specific Scoring Systems"
      },
      {
        "type": "paragraph",
        "text": "These tools integrate tumor biology, staging, and patient-specific variables to inform care. Common examples include:"
      },
      {
        "type": "table",
        "headers": ["Score", "Cancer Type", "Key Variables"],
        "rows": [
          [
            "IPI",
            "Non-Hodgkin lymphoma",
            "Age, LDH, ECOG performance status, Ann Arbor stage, extranodal involvement"
          ],
          [
            "FLIPI",
            "Follicular lymphoma",
            "Age > 60, Ann Arbor stage III-IV, hemoglobin < 12 g/dL, >4 nodal areas, LDH"
          ],
          [
            "R-ISS",
            "Multiple myeloma",
            "β2-microglobulin, albumin, high-risk cytogenetics (e.g., del(17p), t(4;14)), LDH"
          ],
          [
            "IPSS/IPSS-R",
            "Myelodysplastic syndrome",
            "Hemoglobin, ANC, platelets, % marrow blasts, cytogenetics, transfusion dependence"
          ],
          [
            "IPS",
            "Hodgkin lymphoma (adv.)",
            "Age ≥45, stage IV, male sex, low albumin, low hemoglobin, high WBC, low lymphocytes"
          ]
        ]
      },
      {
        "type": "clinical_pearl",
        "text": "These scores often form the basis of treatment algorithms and influence trial eligibility."
      },
      {
        "type": "heading",
        "level": 3,
        "text": "2.1 International Prognostic Index (IPI) Deep Dive"
      },
      {
        "type": "paragraph",
        "text": "The IPI remains the gold standard for aggressive lymphomas. Each risk factor counts as 1 point:"
      },
      {
        "type": "list",
        "items": [
          "Age > 60 years",
          "Elevated LDH",
          "ECOG PS ≥ 2",
          "Ann Arbor stage III/IV",
          ">1 extranodal site"
        ]
      },
      {
        "type": "table",
        "headers": ["Score", "Risk Group", "5-year OS"],
        "rows": [
          ["0-1", "Low", "73%"],
          ["2", "Low-intermediate", "51%"],
          ["3", "High-intermediate", "43%"],
          ["4-5", "High", "26%"]
        ]
      },
      {
        "type": "heading",
        "level": 2,
        "text": "3. Organ-Specific Prognostic Models"
      },
      {
        "type": "paragraph",
        "text": "Used where organ function strongly influences prognosis, especially in primary or metastatic cancers affecting the liver, brain, or kidneys."
      },
      {
        "type": "table",
        "headers": ["Score", "Context", "Use"],
        "rows": [
          [
            "Child-Pugh / MELD",
            "Cirrhosis, HCC",
            "Liver function; influences resection, transplant candidacy"
          ],
          [
            "BCLC",
            "Hepatocellular carcinoma",
            "Combines tumor stage, liver function, PS to guide therapy"
          ],
          [
            "Motzer / IMDC",
            "Renal cell carcinoma",
            "Guides immunotherapy and TKI-based treatments"
          ],
          [
            "RPA / GPA",
            "Brain metastases",
            "Helps select patients for surgery or radiosurgery"
          ]
        ]
      },
      {
        "type": "heading",
        "level": 3,
        "text": "3.1 Child-Pugh Score Components"
      },
      {
        "type": "table",
        "headers": ["Parameter", "1 point", "2 points", "3 points"],
        "rows": [
          ["Bilirubin (mg/dL)", "<2", "2-3", ">3"],
          ["Albumin (g/dL)", ">3.5", "2.8-3.5", "<2.8"],
          ["INR", "<1.7", "1.7-2.3", ">2.3"],
          ["Ascites", "None", "Mild", "Moderate-severe"],
          ["Encephalopathy", "None", "Grade 1-2", "Grade 3-4"]
        ]
      },
      {
        "type": "paragraph",
        "text": "Classification: A (5-6 points), B (7-9 points), C (10-15 points)"
      },
      {
        "type": "heading",
        "level": 2,
        "text": "4. Biomarker-Integrated Scores"
      },
      {
        "type": "paragraph",
        "text": "These tools integrate molecular and genomic data to refine risk. They are often validated to guide adjuvant therapy or surveillance."
      },
      {
        "type": "table",
        "headers": ["Tool", "Cancer Type", "Notes"],
        "rows": [
          [
            "Oncotype DX (21-gene RS)",
            "ER+/HER2− breast cancer",
            "Assesses benefit of chemotherapy vs. endocrine therapy"
          ],
          [
            "Decipher score",
            "Prostate cancer",
            "Predicts metastasis post-prostatectomy"
          ],
          [
            "ctDNA",
            "Colorectal, lung, others",
            "Detects minimal residual disease, early relapse"
          ],
          [
            "PD-L1, TMB",
            "Multiple cancers",
            "Prognostic and predictive for immune checkpoint therapy"
          ]
        ]
      },
      {
        "type": "clinical_pearl",
        "text": "Circulating biomarkers (e.g., ctDNA) are gaining traction in dynamic prognosis post-surgery or therapy."
      },
      {
        "type": "heading",
        "level": 3,
        "text": "4.1 Oncotype DX Recurrence Score Interpretation"
      },
      {
        "type": "table",
        "headers": ["Score Range", "Risk Category", "Chemo Benefit"],
        "rows": [
          ["<18", "Low", "Unlikely"],
          ["18-30", "Intermediate", "Uncertain"],
          [">30", "High", "Likely"]
        ]
      },
      {
        "type": "heading",
        "level": 2,
        "text": "5. Frailty and Functional Assessment Scores"
      },
      {
        "type": "paragraph",
        "text": "Although not traditional prognostic tools, these significantly impact outcomes in older and comorbid patients."
      },
      {
        "type": "table",
        "headers": ["Score", "Function", "Clinical Role"],
        "rows": [
          [
            "CGA / G8 / VES-13",
            "Multidomain frailty assessment",
            "Predicts treatment tolerance, hospitalization, mortality"
          ],
          [
            "CFS (Clinical Frailty Scale)",
            "Visual functional frailty grading",
            "Used in ICU triage, oncology, and surgical planning"
          ],
          [
            "ECOG / KPS / Lansky",
            "Performance status evaluation",
            "Predicts survival, informs treatment thresholds"
          ]
        ]
      },
      {
        "type": "clinical_pearl",
        "text": "Increasingly, these are used in combination with cancer-specific scores to personalize treatment."
      },
      {
        "type": "heading",
        "level": 3,
        "text": "5.1 G8 Screening Tool Components"
      },
      {
        "type": "list",
        "items": [
          "Has food intake declined due to loss of appetite, digestive problems, chewing or swallowing difficulties?",
          "Weight loss during last 3 months?",
          "Mobility issues?",
          "Neuropsychological problems?",
          "BMI <22?",
          "Takes more than 3 medications?",
          "Self-perception of health status?",
          "Age >85 years?"
        ]
      },
      {
        "type": "paragraph",
        "text": "Score ≤14 suggests frailty requiring comprehensive geriatric assessment."
      },
      {
        "type": "heading",
        "level": 2,
        "text": "6. Composite and AI-Driven Models"
      },
      {
        "type": "paragraph",
        "text": "Newer approaches involve nomograms or machine learning algorithms built from real-world and trial datasets."
      },
      {
        "type": "list",
        "items": [
          "MSKCC nomograms: Available for breast, prostate, and sarcoma; combine multiple clinical/pathologic factors",
          "AI algorithms: Integrate EHR data, imaging, and genomics for individualized prognostication",
          "Radiomics and deep learning: Under evaluation to predict outcomes based on imaging phenotypes"
        ]
      },
      {
        "type": "heading",
        "level": 2,
        "text": "7. Clinical Use Case Mapping"
      },
      {
        "type": "table",
        "headers": ["Setting", "Best Prognostic Tool(s)"],
        "rows": [
          [
            "Newly diagnosed lymphoma",
            "IPI, FLIPI"
          ],
          [
            "Post-induction myeloma",
            "R-ISS + response category (e.g., VGPR, sCR)"
          ],
          [
            "Elderly cancer patient",
            "CGA + G8 or CFS + disease-specific score"
          ],
          [
            "Pediatric oncology",
            "Age-adapted scores + Lansky + tumor type-specific models"
          ],
          [
            "Advanced solid tumors (general)",
            "ECOG + organ scores (e.g., Child-Pugh) + frailty assessment"
          ],
          [
            "Clinical trial design",
            "Trial-specific stratification using PS + molecular markers"
          ]
        ]
      },
      {
        "type": "heading",
        "level": 2,
        "text": "8. Summary"
      },
      {
        "type": "paragraph",
        "text": "Prognostic scoring in oncology is evolving to reflect a multidimensional understanding of disease biology, host factors, and treatment context. Key principles include:"
      },
      {
        "type": "list",
        "items": [
          "No one-size-fits-all: Choose tools based on disease, age, and treatment goals.",
          "Combine functional, biochemical, and molecular insights.",
          "Use scores to communicate prognosis, guide therapy, and identify trial candidates.",
          "Stay updated as AI-based models and liquid biomarkers reshape the prognostic landscape."
        ]
      },
      {
        "type": "heading",
        "level": 3,
        "text": "Key Takeaways"
      },
      {
        "type": "numbers",
        "items": [
          "Disease-specific scores (IPI, R-ISS) remain fundamental for treatment planning",
          "Organ function scores (Child-Pugh, MELD) are critical for hepatic malignancies",
          "Molecular tools (Oncotype, ctDNA) add precision to risk stratification",
          "Frailty assessments (G8, CFS) are essential in geriatric oncology",
          "Emerging AI models may integrate all these dimensions in the future"
        ]
      }
    ]
  }